ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
← catalyst calendarNCT07783542 · readout ≤ 798 d
Sponsored by Oruka Therapeutics, Inc. (industry) · ORKA — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
200estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-24
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-20 | estimated | When the study began enrolling |
| Primary completion | Oct 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa (HS)
Interventions
- Drug: ORKA-002
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants achieving HiSCR75 at Week 16
measured Week 16
Related
ORKA · their whole pipeline · Hidradenitis Suppurativa readouts
ORKA's other studiesmost recently updated first
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis Phase 2 · Active, not recruiting
- Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis Phase 2 · Recruiting
- An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis Phase 2 · Recruiting
- ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis Phase 2 · Active, not recruiting
- ORKA-001 in Healthy Volunteers Phase 1 · Completed
Permalink · ORKA's whole pipeline · Catalyst calendar · Every registered study · What changed